Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q3 2026 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, Aug 26, 2026
Slide 1: Q3 Fiscal Year 2026 Financial Results Overview
Q3 FISCAL YEAR 2026 FINANCIAL RESULTS OVERVIEW Aug 26, 2026
Slide 2: Safe Harbor
Thank You for Your Attention Safe Harbor This presentation contains forward- successfully adapt its cost structures to The company assumes no obligation to looking statements (including, without continuing changes in business update the information in these limitation, information, and future condit
Slide 3: Agilent 3Q26 Results
Agilent 3Q26 Results 7.3% revenue growth(1)(2) beats high-end of guidance by 140 bps(2) Operating margins also above guide by 190 bps (3) $ • Topline strength led by high-single-digit instrument growth Revenue Operating Margin EPS $1.88B 28.3% $1.62 (2) (2) and nearly 30% growth in our specialty CDM
Slide 4: Q3 results
Q3 results LDG +10% • Low double-digit LC growth against a mid-teens compare Core Growth(1)(2) 23.5% • Nearly 30% growth in Advanced once again Operating Margin(2)(3) +11% Reported Therapeutics Division demonstrate compounding AMG +7% • Strong demand supported by semiconductor momentum value of the
Slide 5: Americas and APAC (including China) deliver strong broad-based growth
GEOGRAPHY PRODUCT TYPE Core Revenue Growth by Geography Americas and APAC Americas 40% of Agilent Revenue(2) (including China) 2% (1) +9% (1) deliver strong broad- 10% Europe (1) 27% of Agilent Revenue(2) based growth Asia-Pacific (APAC) 33% of Agilent Revenue(2) (1) Core or organic constant currenc
Slide 6: Q3 revenue mix
GEOGRAPHY PRODUCT TYPE Q3 revenue mix % of total revenue 66% Recurring revenue mix remains Consumables healthy Services Informatics Robust instrument growth, book-to- bill ≥1.0x for 10th consecutive quarter Instruments 34% 06
Slide 7: Exceptional execution supported by continued improvement in largest end markets
Q3 Core Share Growth(1) of Agilent Results Revenue(2) +12% 38% Biotech momentum, robust GLP-1 contribution and Pharma nearly 30% growth in Advanced Therapeutics Division Q3 REVENUE Diagnostics & +6% 15% Strength driven by Companion Diagnostics demand, Exceptional Clinical Genomics growth; Pathology
Slide 8: FY26 Guidance
FY26 Net (1) $7.49B $7.51B Guidance Revenue ($) +$60M at the midpoint vs. prior guide Increasing core revenue Core Revenue +5.8% +6.0% +1.6% FX growth(2), margin expansion(3) Growth(2) +65 bps at the midpoint vs. prior guide and EPS outlook(4) (3) Operating Margins >130 bps YoY Updated outlook refle
Slide 9: 4Q26 Guidance
4Q26 Guidance (1) (3) Net Revenue ($B) $1.98B $2.00B Expect YTD momentum to Core Revenue continue Growth(2) +5.2% +6.2% -0.1% FX Reflects healthy demand trends across largest end markets EPS (3) $1.71 $1.74 $4M Net Interest + Other Inc/(Exp) 283M Share Count Q4 Q4 (1) Based on forecasted currency ex
Slide 10: Get in touch with us
Get in touch with us Trusted Answers investor_relations@agilent.com www.investor.agilent.com